U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07561125) titled 'Effects of IVIG for BPD in Preterm Infant Born at 28 Weeks and Below' on April 26.
Brief Summary: It is intended to examine the short-term and long-term efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms born at 28 weeks and below. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Bronchopulmonary Dysplasia
Intervention:
DRUG: intravenous immunoglobulin
1 g/kg/day for the first 2 days, 0.5 g/kg/day f...